A Multicentric, Open label, Randomized, Comparative, Clinical Study evaluating Safety and Efficacy of Fixed Dose Combination of Trypsin 48 mg plus Bromelain 90 mg plus Rutoside Trihydrate 100 mg enteric coated tablet versus Serratiopeptidase 10 mg enteric coated tablet in patients for healing potential in surgical wounds after minor surgery

Macleods Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male or female patients who are 18 to 65 years of age with surgical wounds after minor surgery.
•2.Patients able to follow all study directions and commit to come at all follow-up visits as per the protocol. In addition, subjects must be willing to accept the restrictions of the study.
•3.Subjects have the willingness and ability to understand and provide written informed consent to participate in the study.

•1.Patients with Uncontrolled diabetes mellitus or any other metabolic disorder.
•2.Patients with known hypersensitivity to any of the study related drugs.
•3.Patient with hepatic and/or renal disorder, bleeding disorders, menorrhagia, hematuria and hematemesis.
•4.Patients taking medicines such as tetracycline group of drugs, amoxicillin, aspirin, anticoagulants including clopidogrel should be excluded
•5.Patients who are currently enrolled in another clinical investigation or have been enrolled in any surgical wound trial within a period of 30 days prior to enrollment in this study.
•6.Women of child bearing age not using any contraceptive
•7.Pregnant or nursing women
•8.Any other condition that, in the opinion of the investigator, does not justify the inclusion of the subject in the study.

发起方